ATRC AtriCure, Inc.

CIK 0001323885 37 ready 8-Ks latest July 23, 2026, 4:00 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 37

Latest filing July 23, 2026, 4:00 PM ET

Top materiality 0.85

Event mix earnings ×27 · other_material ×6 · other ×3

Sentiment 22 pos · 2 neg · 13 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for ATRC

Highest-materiality recent filing

AtriCure Q2 revenue $71.4M (+74.8% YoY); aMAZE trial fails efficacy endpoint

August 4, 2021, 7:59 PM ET other material materiality 0.85 negative item 2.02 item 7.01 item 9.01

Revenue $71.4M, up 74.8% YoY (73.5% constant currency); U.S. $60.1M (+78.4%), international $11.3M (+57.9%).
Net loss per share $0.36; adjusted loss per share $0.30; adjusted EBITDA loss $2.7M.

Read filing →

July 23, 2026, 4:00 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

AtriCure Q2 2026 revenue $153.6M (+12.8% YoY); net income $9.0M vs loss a year ago

Worldwide revenue $153.6M, up 12.8% YoY (12.4% constant currency); U.S. revenue $125.6M (+13.6%).
May 6, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

AtriCure Q1 revenue $141.2M (+14.3%); corrects FY2026 guidance to rev $600-610M, adj EBITDA $80-82M

Q1 revenue $141.2M (+14.3% YoY); net income $0.1M, breakeven EPS.
May 5, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

AtriCure Q1 2026 revenue $141.2M (+14.3%); net income $0.1M; adj. EBITDA $17.1M

Worldwide revenue $141.2M (+14.3% YoY); U.S. $116.2M (+14.9%), international $25.0M (+11.5%).
February 17, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

AtriCure Q4 revenue $140.5M (+13.1% YoY); guides FY26 revenue $600-610M

Q4 2025 revenue $140.5M (+13.1% YoY); net income $1.8M ($0.04 EPS) vs net loss $0.33 per share in Q4 2024.
January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 1.01 item 2.02 item 2.03 item 9.01 ◈ Material Agreements

AtriCure reports preliminary Q4 revenue $140.5M (+13%), FY 2025 $534.5M (+15%); guides 2026 revenue ~$600-610M

Q4 2025 revenue $140.5M (+13% YoY); US $114.3M (+13%), intl $26.2M (+15% as reported).
October 29, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

AtriCure Q3 revenue $134.3M (+15.8% YoY); net loss narrows to $0.3M; raises FY2025 outlook

Revenue $134.3M, +15.8% YoY (+15.1% constant currency); US $109.3M (+14.5%), intl $25.0M (+22.0%).
October 29, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

AtriCure Q3 revenue +15.8% to $134.3M, net loss narrows to $0.3M; raises 2025 outlook

Revenue of $134.3M (+15.8% YoY); U.S. $109.3M (+14.5%), international $25.0M (+22.0%).
July 29, 2025, 7:59 PM ET earnings materiality 0.78 positive item 2.02 item 9.01

AtriCure Q2 revenue up 17%; net loss narrows; raises 2025 outlook

Worldwide revenue $136.1M (+17.1% YoY); U.S. $110.6M (+15.7%), Int'l $25.6M (+23.3%).
April 29, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

AtriCure Q1 revenue $123.6M (+13.6% YoY); net loss improves to $6.7M from $13.2M

Revenue $123.6M (+13.6% YoY; +14.1% constant currency); U.S. $101.1M (+12.1%), International $22.5M (+20.8%).
February 12, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

AtriCure Q4 revenue $124.3M (+16.6% YoY); guides FY25 rev $517-527M

Q4 revenue $124.3M (+16.6%); full year revenue $465.3M (+16.5%).
January 13, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

AtriCure reports preliminary Q4 revenue $124.3M (+17%); guides 2025 revenue $517-527M

Preliminary Q4 2024 revenue $124.3M (+17% YoY as reported and constant currency).
October 29, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

AtriCure Q3 2024: revenue $115.9M (+17.9%), loss $0.17/sh, positive cash flow $16.3M

Worldwide revenue $115.9M, up 17.9% YoY; U.S. $95.5M (+16.8%), Intl $20.5M (+23.3%).
July 30, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

AtriCure Q2 2024 revenue $116.3M (+15.2% YoY); net loss $0.17/share

Worldwide revenue $116.3M, up 15.2% YoY (15.4% constant currency); U.S. $95.5M (+12.5%), international $20.7M (+29.4%).
May 1, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

AtriCure Q1 revenue $108.9M (+16.4% YoY); net loss per share $0.28

Worldwide revenue $108.9M, up 16.4% YoY (16.3% constant currency); U.S. revenue $90.2M (+15.4%), international $18.6M (+21.5%).
February 15, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

AtriCure Q4 revenue $106.5M (+21%), full-year adj EBITDA positive $19.4M; guides 2024 rev ~$459-466M

Q4 2023 revenue $106.5M (+21% YoY); full-year revenue $399.2M (+20.8%).
January 8, 2024, 6:59 PM ET earnings materiality 0.75 positive item 1.01 item 1.02 item 2.02 item 2.03 item 9.01 ◈ Material Agreements ×2◈ Debt Financings◈ Earnings Releases

AtriCure prelim Q4 rev $106.5M (+21% YoY); new $125M ABL credit facility

Q4 2023 preliminary revenue $106.5M (+21% YoY); full year revenue $399.2M (+21% YoY).
November 1, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

AtriCure Q3 revenue $98.3M (+18% YoY); positive adjusted EBITDA $4.7M

Worldwide revenue $98.3M, up 18.1% YoY; U.S. $81.7M (+17.1%), International $16.6M (+23.2%).
July 25, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

AtriCure Q2 revenue $100.9M (+19.4% YoY); net loss narrows to $5.1M, adjusted EBITDA positive $8.0M

Worldwide revenue $100.9M, up 19.4% YoY; U.S. $84.9M (+19.1%), international $16.0M (+20.7%).
May 2, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

AtriCure Q1 revenue $93.5M (+25.4% YoY), net loss narrows to $6.5M, positive adj. EBITDA $1.9M

Revenue $93.5M (+25.4% YoY); US $78.2M (+25.6%), Intl $15.3M (+24.4%).
February 21, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×3

AtriCure Q4 revenue $88M (+20.2% YoY); FY2022 revenue $330.4M (+20.4%); guides FY2023 rev $380-387M

Q4 2022 revenue $88.0M, up 20.2% YoY; U.S. revenue $73.9M (+20.7%), international $14.1M (+17.8%).
January 9, 2023, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

AtriCure reports Q4 2022 preliminary revenue $88M (+20% YoY); guides 2023 rev $380-387M

Q4 2022 revenue ~$88M (U.S. $73.9M, intl $14.1M), up 20% YoY.
November 1, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

AtriCure Q3 revenue $83.2M (+18.1% YoY); net loss $0.27/share; guides FY2022 rev ~$328-333M

Revenue $83.2M, up 18.1% YoY (19.8% constant currency). US revenue $69.8M (+21.3%).
August 2, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

AtriCure Q2 2022 revenue $84.5M (+18.4%); net loss $0.32/share; FY guidance unchanged

Revenue $84.5M (+18.4% YoY; +19.8% constant currency); U.S. $71.3M (+18.6%), international $13.3M (+17.3%).
May 3, 2022, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01

AtriCure Q1 revenue $74.6M (+25.8% YoY); guides FY22 rev $318-330M

Revenue $74.6M, up 25.8% YoY; U.S. $62.3M (+23.8%), intl $12.3M (+37.2%).
April 13, 2022, 7:59 PM ET other material materiality 0.60 positive item 7.01 item 9.01

AtriCure launches EnCompass Clamp for cardiac ablation in US

FDA 510(k) clearance for cardiac tissue ablation; features parallel closure, uniform pressure, custom RF power.
February 15, 2022, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

AtriCure Q4 revenue $73.2M (+26.8% YoY); guides FY22 rev $315-330M

Q4 2021 revenue $73.2M (+26.8% YoY); U.S. $61.2M (+29.1%), Intl $12.0M (+16.3%).
January 10, 2022, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01

AtriCure reports preliminary Q4 revenue $73.2M (+27% YoY), guides FY2022 $315-330M

Q4 2021 revenue ~$73.2M (+27% YoY); U.S. $61.2M (+29%), Intl $12.0M (+16% as reported).
August 4, 2021, 7:59 PM ET other material materiality 0.85 negative item 2.02 item 7.01 item 9.01

AtriCure Q2 revenue $71.4M (+74.8% YoY); aMAZE trial fails efficacy endpoint

Revenue $71.4M, up 74.8% YoY (73.5% constant currency); U.S. $60.1M (+78.4%), international $11.3M (+57.9%).

Executive changes

Appointed

Shlomi Nachman

director

ATRC · AtriCure, Inc.

Effective: 2024-01-04
Filed: January 4, 2024, 6:59 PM ET

elected Shlomi Nachman to serve as a director until the next Annual Meeting of Stockholders.

Earnings & guidance

2026-Q1 EPS reported $0.00 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event earnings

22 positive 2 negative 13 neutral

source · ATRC on sec.gov